Clinical trial NCT00174915 - References

Gout — Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.

Citation(s)

•   Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N
  Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):585-91. doi: 10.1080/15257770802136032.
•   Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL
  Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680.
•   Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N
  Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized,
•   Wortmann RL, Macdonald PA, Hunt B, Jackson RL
  Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010 Dec;32(14):2386-97. doi: 10.1016/j.clinthera.2011.01.008.

A Phase 3, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout.

Details for clinical trial NCT00174915